An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy Volunteers

The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers

Start Date23 Dec 2023

Sponsor / Collaborator

Boryung Corp.

NCT05930028

/ CompletedPhase 3

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

Start Date13 Jul 2023

Sponsor / Collaborator

Boryung Corp.

NCT05372380

/ CompletedPhase 1

An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR1017-1" and "BR1017-2" in Healthy Volunteers

To evaluate the influence of BR1017-1 and BR1017-2 on pharmacokinetics and safety when administered separately or co-administered to healthy volunteers.

Start Date09 May 2022

Sponsor / Collaborator

Boryung Corp.

100 Clinical Results associated with Fimasartan Potassium Trihydrate

100 Translational Medicine associated with Fimasartan Potassium Trihydrate

100 Patents (Medical) associated with Fimasartan Potassium Trihydrate

134

Literatures (Medical) associated with Fimasartan Potassium Trihydrate

01 Nov 2025·CLINICAL THERAPEUTICS

Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial

Article

Author: Park, Sang-Don ; Kim, Kye Hun ; Jeong, Hyeonju ; Lee, Jung-Hee ; Sung, Ki-Chul ; Kang, Woong Chol ; Son, Jang-Won ; Cho, Deok-Kyu ; Lee, Sang-Yeub ; Hahn, Joo-Yong ; Hong, Soon Jun ; Park, Jong-Pil ; Yoon, Young Won ; Rhee, Moo-Yong ; Cho, Yoon Haeng ; Cho, Goo-Yeong ; Ahn, Jong-Hwa ; Cha, Tae-Joon ; Cha, Kwang Soo ; Ahn, Kye Tack ; Moon, Jae Youn ; Ha, Jong-Won ; Shin, Jinho ; Kim, Ju Hyeon ; Yi, Jeong-Eun ; Lee, Jin Bae

BACKGROUND:

Essential hypertension and primary hypercholesterolemia are common and independent cardiovascular risk factors that frequently coexist and warrant integrated management. This study aimed to evaluate the efficacy and safety of triple combination therapy (FMS + ATO/EZE) with Fimasartan (FMS), atorvastatin (ATV), and ezetimibe (EZE) compared with atorvastatin/ezetimibe (ATO/EZE) dual therapy or Fimasartan (FMS) monotherapy in patients with hypertension and hypercholesterolemia.

METHODS:

This multicenter, randomized clinical trial was conducted across 25 clinical trial institutions in the Republic of Korea. A total of 315 participants were screened, of whom 148 eligible participants were randomized to receive FMS + ATO/EZE (n = 49), ATO/EZE (n = 49), or FMS (n = 50). The primary efficacy endpoints were the change in mean sitting systolic blood pressure (msSBP) from baseline to week 8 in the FMS + ATO/EZE group compared with that in the ATO/EZE group and the percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to week 8 in the FMS + ATO/EZE group compared with that in the FMS group. Safety was assessed based on treatment-emergent adverse events (TEAEs).

RESULTS:

In the full analysis set, the FMS + ATO/EZE group demonstrated superior reduction in msSBP compared to the ATO/EZE group (least squares [LS] mean difference: -7.26 ± 2.84 mm Hg; 95% confidence interval [CI]: -12.91, -1.61; P = 0.0124). Similarly, the percentage reduction in LDL-C was significantly greater in the FMS + ATO/EZE group than in the FMS group (LS mean difference: -58.02% ± 4.03%; 95% CI: -66.03, -50.02; P < 0.0001). The incidence of TEAEs was comparable across treatment groups: FMS + ATO/EZE (20.83%), ATO/EZE (22.45%), and FMS (16.00%) (P = 0.7030). Serious adverse events occurred in 1.36% of the total safety population, without significant difference between the groups (P = 0.5480).

CONCLUSIONS:

Triple combination therapy with FMS + ATO/EZE was superior to dual therapy or monotherapy in reducing both BP and LDL-C levels in patients with essential hypertension accompanied by primary hypercholesterolemia. The safety profile was comparable with that of the individual components, confirming the tolerability and safety of FMS + ATO/EZE therapy. However, the 8-week follow-up period and enrollment of an exclusively Korean cohort may limit the assessment of long-term effects and generalizability to other ethnic populations.

01 Nov 2024·EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Novel Fimasartan Fluidized Solid Dispersion and Its Tablet: Preparation, Crystallinity, Solubility, Dissolution, and Pharmacokinetics in Beagle Dogs

Article

Author: Choi, Han-Gon ; Shin, Dong Chul ; Jin, Sung Giu ; Cho, Jung Hyun ; Ud Din, Fakhar

BACKGROUND AND OBJECTIVES:

Fimasartan, an angiotensin II receptor antagonist, exhibits low bioavailability due to its poor solubility; consequently, using solubilization technologies is essential to improve its bioavailability. In this study, novel fimasartan fluidized solid dispersion (FFSD) was developed using a fluid bed granulator to enhance the drug solubility and oral bioavailability.

METHODS:

An appropriate FFSD was prepared in 50% ethanol using a fluid bed granulator, and its drug dissolution, morphology, and crystallinity were evaluated in comparison to the powdered drug. Moreover, the dissolution in various pH conditions and pharmacokinetics of the FFSD tablet in beagle dogs were investigated compared to the commercial fimasartan tablet.

RESULTS:

Among the hydrophilic polymers tested, hydroxypropyl methylcellulose (HPMC) showed the highest solubility. The FFSD, composed of fimasartan, HPMC, and microcrystalline cellulose at the weight ratio of 20:10:25, gave a granular aggregation of several particles with a smooth surface. The drug in this FFSD existed as an amorphous state, leading to a greatly increased drug dissolution. The FFSD tablet was prepared by compressing a mixture of FFSD, mannitol, croscarmellose sodium, and magnesium stearate at the weight ratio of 55:40:5:1. The FFSD tablet gave significantly higher drug dissolution, plasma concentrations, maximum plasma concentration (C_max) and area under the whole blood concentration-time curve (AUC) values than did the commercial fimasartan tablet. In the beagle dogs, the FFSD tablet (140.39 ± 27.40 ng·h/ml) had about a 1.7-fold higher AUC than the commercial fimasartan tablet (80.58 ± 22.18 ng·h/ml), indicating an enhancement in the bioavailability.

CONCLUSIONS:

This novel FFSD tablet could be a potential oral pharmaceutical product with the improved oral bioavailability of fimasartan.

01 Sep 2024·Analytical and Bioanalytical Chemistry

In situ metabolomic analysis of osteonecrosis of the femoral head (ONFH) using MALDI MSI

Article

Author: Zhang, Yinguang ; Li, Jiantao ; Han, Yehua ; Nie, Honggang ; Li, Chen ; Wang, Yinghao ; Di, Shuangshuang ; Sheng, Yiqi ; Jia, Lan ; Liu, Jikun

Osteonecrosis of the femoral head (ONFH) is a common orthopedic disease characterized by disability and deformity. To better understand ONFH at molecular level and to explore the possibility of early diagnosis, instead of diagnosis based on macroscopic spatial characteristics, a matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) method was developed for ONFH disease for the first time. The most challenging step for ONFH MSI is to deal with human bone tissues which are much harder than the other biological samples studied by the reported MSI studies. In this work, the MSI sectioning method of hard bone tissues was established using tender acids and a series of test criteria. Small-molecule metabolites, such as lipids and amino acids, were detected in bone sections, realizing the in situ detection of spatial distribution of biometabolites. By comparing the distribution of metabolites from different regions of normal femoral head, ONFH bone tissue (ONBT), and adjacent ONFH bone tissue (ANBT), the whole process of femoral head from normal stage to necrosis was monitored and visualized at molecular level. Moreover, this developed MSI method was used for metabolomics study of ONFH. 72 differential metabolites were identified, suggesting that disturbances in energy metabolism and lipid metabolism affected the normal life activities of osteoblasts and osteoclasts. This study provides new perspectives for future pathological studies of ONFH.

News (Medical) associated with Fimasartan Potassium Trihydrate

08 Dec 2023

·synapse.patsnap.com

What are HMG-CoA reductase inhibitors and how do you quickly get the latest development progress?

HMG-CoA reductase is an enzyme that plays a crucial role in the human body's cholesterol synthesis pathway. It is responsible for catalyzing the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) to mevalonate, a key precursor in the production of cholesterol. By regulating the activity of HMG-CoA reductase, the body can control the amount of cholesterol synthesized. This enzyme is the target of statin drugs, which inhibit its activity, leading to a reduction in cholesterol levels. Maintaining proper HMG-CoA reductase function is essential for maintaining cholesterol homeostasis and preventing the development of cardiovascular diseases. HMG-CoA reductase inhibitors, also known as statins, are a class of drugs used to lower cholesterol levels in the body. The first statin, lovastatin, was approved by the FDA in 1987. Since then, several other statins have been developed, including atorvastatin, simvastatin, and rosuvastatin. Statins work by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing cholesterol levels, statins can help prevent heart attacks, strokes, and other cardiovascular diseases. In addition to their cholesterol-lowering effects, statins have been shown to have other beneficial effects, such as reducing inflammation and improving endothelial function. They have also been investigated for their potential to treat other conditions, such as Alzheimer’s disease, multiple sclerosis, and certain types of cancer. The future of HMG-CoA reductase inhibitors looks promising, with ongoing research into new statins and other cholesterol-lowering drugs. Researchers are also investigating the potential of statins to treat other diseases, such as osteoporosis and autoimmune disorders. However, there are also concerns about the long-term effects of statin use, such as an increased risk of diabetes and liver damage. As such, further research is needed to fully understand the benefits and risks of these drugs. The mechanism of action of HMG-CoA reductase inhibitorsHMG-CoA reductase inhibitors are a class of drugs commonly known as statins. From a biomedical perspective, these drugs are used to lower cholesterol levels in the blood. They work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the production of cholesterol in the liver. By blocking this enzyme, statins reduce the amount of cholesterol synthesized in the body, leading to a decrease in LDL (low-density lipoprotein) cholesterol, often referred to as "bad" cholesterol. Lowering LDL cholesterol levels can help prevent the development of cardiovascular diseases such as heart attacks and strokes. Additionally, statins may have other beneficial effects, such as reducing inflammation and improving the function of blood vessels. HMG-CoA reductase inhibitors are commonly prescribed to individuals with high cholesterol levels or those at risk of cardiovascular diseases. Catalog of HMG-CoA reductase InhibitorsThe currently marketed HMG-CoA reductase inhibitors include: Ezetimibe/Pitavastatin CalciumAtorvastatin/FimasartanFenofibrate/Pitavastatin CalciumAmlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin CalciumAmlodipine Besylate/Olmesartan Medoxomil/Rosuvastatin CalciumAtorvastatin Calcium Hydrate/Metformin HydrochlorideAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilPitavastatin MagnesiumAmlodipine/Losartan Potassium/Rosuvastatin CalciumValsartan/Rosuvastatin CalciumFor more information, please click on the image below. What is the purpose of using HMG-CoA reductase inhibitors?HMG-CoA reductase inhibitors, are used to lower cholesterol levels in the body. They are used adjunctively with diet and exercise to treat and manage hypercholesterolemia (high cholesterol in blood) and for primary and secondary prevention of coronary heart disease. For more information, please click on the image below to log in and search. How can I get the most recent advancements in HMG-CoA reductase inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of HMG-CoA reductase inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

15 Jun 2022

·www.prnewswire.com

Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study

The global antihypertensive drugs market is likely to be driven by the introduction of novel drug/therapeutic compounds with disease-modifying capabilities and better effectiveness North America's considerable market share is due to high uptake of antihypertensive medications in the US and an increasing number of new drug approvals by the US FDA ALBANY, N.Y., June 15, 2022 /PRNewswire/ -- The revenue of antihypertensive drugs market stood at US$ 30.2 Bn in 2021. The global market is likely to develop at a CAGR of 3% during the forecast period, from 2022 to 2031. The global antihypertensive drugs market is likely to attain a valuation of US$ 40 Bn by 2031. The global antihypertensive drugs market is anticipated to be propelled by a rise in the launch of novel pharmaceuticals and diagnostic agents. Besides, major industrial advancements such as partnerships and set-up of R&D facilities are also expected to fuel antihypertensive drugs market expansion. The global market is expected to be driven by rising disposable income as well as the introduction of innovative disease-modifying treatments during the forecast period. Firms in the antihypertensive drugs industry are projected to benefit from significant expansion in telemedicine and e-Health applications in the long run. In order to meet treatment objectives, most hypertension patients need a mix of antihypertensive medications. In an effort to boost efficacy of the first drug, combination therapy involves adding some other family of blood pressure medication to it. There is a significant unmet need for antihypertensive medications, indicating a shortage of viable products. This creates a huge opportunity for new market entrants to profit from unmet demands, owing to patient non-compliance or poor compliance with already existing medicines. Antihypertensive drug trends in stroke patients could reveal critical insights into secondary prevention gaps that are likely to help guide future treatments. In order to acquire a competitive advantage over other market participants, healthcare businesses are strengthening R&D in the fields of resistant hypertension therapy and genomics. Request Brochure of Antihypertensive Drugs Market Research Report – Key Findings of Market Report Innovative antihypertensive medications and pharmacological treatments, which successfully target illness progression, are predicted to have promising benefits. Novel medicines for disorders such as calcium channel blockers (CCB), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are projected to transform the existing picture in the global antihypertensive pharmaceuticals market. The market is projected to be driven by the introduction of new products that are more safe and more efficient. A few of such medications under development are diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) by Takeda Pharmaceuticals and fimasartan/amlodipine (phase III) by Boryung Pharmaceutical. The primary hypertension category is expected to lead the global market in the forthcoming years. Over the last decade, hypertension has gradually become a major public health issue. Salt consumption among children in developed countries is often higher than the recommended amount. In developing countries, a similar tendency prevails, which is likely to act as the largest opportunity for antihypertensive drugs. In the initial years of life, a positive sodium balance is required for development. Nevertheless, excessive salt consumption might have negative cardiovascular implications, which is expected to result in driving market demand for antihypertensive drugs Request for Analysis of COVID-19 Impact on Antihypertensive Drugs Market – Global Antihypertensive Drugs Market: Growth Drivers Based on medication, the combination therapy category is expected to lead the market with a significant percentage in terms of revenue. This is one of the key market segments in antihypertensive drugs. This segment is being driven by an increase in the geriatric population suffering from comorbid illnesses like congenital heart disease and an emphasis on combination medications. As a result, companies are ramping up the manufacturing of combination antihypertensive medications to suit the demands of senior individuals with many medical conditions. In 2021, the hospital pharmacies category led the global market by distribution channel. Hospital pharmacies often have a wide selection of pharmaceuticals on reserve, including specialist and experimental drugs. In order to diversify their revenue streams, hospital pharmacists are extending the supply of hypertension management devices. Get Exclusive PDF Sample Copy of Antihypertensive Drugs Market Report – Global Antihypertensive Drugs Market: Key Players Some of the key market players are Pfizer, Inc. Takeda Pharmaceutical Company Limited Boehringer Ingelheim GmbH Daiichi Sankyo Company, Limited F. Hoffmann-La Roche Ltd. Sanofi S.A. Make an Enquiry Before Buying – Global Antihypertensive Drugs Market: Segmentation Therapy Type Diuretics Angiotensin Converting Enzyme Inhibitors Angiotensin Receptor Blockers Beta-blockers Vasodilators Calcium Channel Blockers Renin Inhibitors Alpha-blockers Others Type Primary Hypertension Secondary Hypertension Medication Type Monotherapy Combination Therapy Fixed Dose Combinations Distribution Channel Retail Pharmacies Hospital Pharmacies Online Pharmacies Others Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Reports by Transparency Market Research: Erectile Dysfunction Drugs Market: Increase in use of such drugs to treat the above mentioned disease conditions will continue to encourage the use of erectile dysfunction drugs, thereby driving the erectile dysfunction drugs market. Point-of-Care Diagnostics Market: Increase in incidence of diabetes, cancer, and other chronic diseases, and technological advancements in the field of point-of-care that has resulted in new and innovative products are projected to drive the global point-of-care diagnostics market during the forecast period. Rapid Medical Diagnostic Kits Market: Widespread availability, aging population, and shift in technological & commercial environment are projected to drive the global rapid medical diagnostics kits market during the forecast period. In Vitro Diagnostics Market: Rise in health care expenditure due to increase in awareness about various health care programs and availability of cost-effective diagnostic methods are likely to augment the global in vitro diagnostics market. Pressure Ulcer Diagnostics Market: Rise in awareness about pressure ulcer diagnostic tools & tests, and surge in COVID-19 patients suffering from pressure ulcers & other chronic diseases are anticipated to boost the growth of the global pressure ulcer diagnostics market during the forecast period. Lyme Disease Diagnostics Market: The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market. Hemostasis Diagnostics Market: Rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period. Meningitis Diagnostic Testing Market: The EMEA meningitis diagnostic testing market is expected to reach the value of US$ 83.51 Mn by the end of 2031 and to expand at a CAGR of 3.7% from 2021 to 2031. Rapid diagnostic tests are significantly changing the EMEA meningitis diagnostic testing market. About Us Transparency Market Research (TMR) is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. Corporate Headquarter Downtown 1000 N. West Street Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

Diagnostic Reagents

100 Deals associated with Fimasartan Potassium Trihydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fimasartan Potassium Trihydrate	C09CA10	DB09279

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	Mexico	Boryung Holdings Co., Ltd.	15 Sep 2014
Essential Hypertension	South Korea	Boryung Corp.	09 Sep 2010
Type 2 diabetes mellitus with established diabetic nephropathy	South Korea	Boryung Corp.	09 Sep 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	South Korea	Boryung Corp.	11 Feb 2016
Kidney Diseases	Phase 3	South Korea	Boryung Holdings Co., Ltd.	24 Nov 2015
Primary hypercholesterolemia	Phase 1	South Korea	Boryung Corp.	23 Dec 2023
Dyslipidemias	Clinical	South Korea	Boryung Holdings Co., Ltd.	21 Mar 2020
Diabetic Nephropathies	Preclinical	South Korea	Boryung Holdings Co., Ltd.	-
Myocardial Infarction	Preclinical	South Korea	Boryung Holdings Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02620306 (FANTASTIC, Pubmed) Manual	Phase 3	Non-diabetic Chronic Kidney Disease	341	Fimasartan	qofmyffypd(mhrivnvjav) = eozfobhduz tizavqfgnw (vrupmkktls )	Superior	20 Sep 2022
				Losartan	qofmyffypd(mhrivnvjav) = eclvmevvpj tizavqfgnw (vrupmkktls )
NCT02495324 (FAST, Pubmed) Manual	Phase 4	Essential Hypertension	312	Fimasartan	dwmjwvmakq(ylamhrbrie) = kgjxlerrmk nzpdbetqmo (grexzxjarg, 15.07) View more	Positive	23 Jan 2020
				Valsartan	dwmjwvmakq(ylamhrbrie) = xiwdpgivhi nzpdbetqmo (grexzxjarg, 13.87) View more
NCT02248961 (CTgov)	Phase 3	Hypertension \| Essential Hypertension	179	Fimasartan (Kanarb (Fimasartan))	knndufjmeb(gnjwmqmcpg) = nbalqtnakx uhwtvvpctn (kdsgxcvdja, 5.9) View more	-	06 May 2019
				Losartan (Cozaar® (Losartan))	knndufjmeb(gnjwmqmcpg) = kqduggsprs uhwtvvpctn (kdsgxcvdja, 5.9) View more
NCT00922480 (CTgov)	Phase 3	Essential Hypertension	506	Losartan (Control: Losartan / Week 12 -ITT)	qmrdxppsca(odfvxacxod) = qgplsrlkoh nwwnluoneh (skorejfrgu, 7.72)	-	13 Feb 2018
				Fimasartan (Test: Fimasartan / Week 12 -ITT)	qmrdxppsca(odfvxacxod) = dlzgeemkap nwwnluoneh (skorejfrgu, 7.53)
NCT00922441 (CTgov)	Phase 2	Essential Hypertension	92	Fimasartan 60 mg group (Fimasartan 1)	akuqtfrvve(omeikxxuqx) = ewatyleair orzmtjyosd (womzgcpivg, zlsqwiqhfi - tnpbjhedrh) View more	-	13 Feb 2018
				Fimasartan 120 mg group (Fimasartan 2)	akuqtfrvve(omeikxxuqx) = sotqpvfjss orzmtjyosd (womzgcpivg, rwkrkzsidc - hlonyvugwf) View more
NCT01878201 (Pubmed \| Korean J Intern Med) Manual	Phase 2	Hypertension	75	fimasartan	akeedvrtcr(cmogwwkqax) = xmecccwxjq ezmcedcptb (deergvztns, 11.9) View more	Positive	01 Nov 2017
				valsartan	akeedvrtcr(cmogwwkqax) = otrkzmyrpt ezmcedcptb (deergvztns, 11.6) View more
NCT02466490 (Pubmed) Manual	Phase 3	Essential Hypertension	272	fimasartan	bvignzhpfp(fvfdclftui) = yqxhowvlie nviardystl (adydcpgaxn, 14.1) View more	Positive	01 Oct 2017
NCT01135212 (Pubmed \| Clin Ther)	Phase 3	Essential Hypertension	290	Fimasartan 60 mg	azczcsauia(midbrjxhnb) = a slightly higher, but statistically not significant, incidence of hepatic enzyme elevation in fimasartan 120 mg diofryhzfg (rcalpyowfb )	Positive	01 Jun 2016
				Fimasartan 120 mg
PP.35.24 (ESH2015)	Phase 3	-	-	Fimasartan 30 mg	bcnkqhylqb(yprmwncpre) = dxtroxteek vxmnankzyx (exbsxenwcy, 2.00)	Positive	01 Jun 2015
				Valsartan 80 mg	bcnkqhylqb(yprmwncpre) = tckfxunmxo vxmnankzyx (exbsxenwcy, 2.15)
NCT01672476 (Pubmed \| Clin Ther)	Phase 3	Hypertension	293	30-mg Fimasartan	matietnwjd(xyvlydpuie) = sxupbrlzva ellvvmirrv (eczxxkgtou ) View more	Positive	01 Oct 2014
				Placebo	matietnwjd(xyvlydpuie) = xmjbxvzivh ellvvmirrv (eczxxkgtou ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis